Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan vs esomeprazole in reflux esophagitis
CTR20212441Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in erosive esophagitis (EE), gastroesophageal reflux disease (GERD), sponsored by Daewoong Pharmaceutical. Started Oct 2021; status: completed.
02
Drugs
fexuprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on CTR20212441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212441.